ArticleScientific reports2025
Chemical evaluation of arbequina extra virgin olive oil with in silico analysis of its key phenolic compounds targeting LDL metabolism.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bempedoic acid within the phase ternary diagram governing biliary cholesterol solubilization and gallstone risk.Journal of lipid research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The chemical properties of extra virgin olive oil (EVOO) from Arbequina variety grown in Türkiye were evaluated, and its major phenolic compounds (PC) (oleocanthal, oleacein, luteolin and tyrosol) were compared with drugs (bempedoic acid and ezetimibe) involved in LDL metabolism through in silico analyses. The fatty acids composition (FA), PC and volatile organic compound (VC) profiles of EVOO obtained from Arbequina olive were evaluated via chromatographic methods (GC-FID, HPLC). The quality parameters, including total phenolic content (TPC), pigment content, peroxide value (PV), free fatty acid levels (FFA) and absorption coefficients, were determined via spectrophotometric methods. ADMET profiles, density functional theory (DFT), molecular docking, and the biological targets and activities of oleocanthal, oleacein, luteolin, tyrosol, bempedoic acid and ezetimibe were calculated and compared. Oleocanthal, oleacein, and luteolin completely passed the rules of Lipinski, Ghose, Veber, Egan, and Muegge, whereas only luteolin met the optimum ranges of all the criteria on the radar map. All 4 PC strongly inhibited OATP1B1 and OATP1B3, whereas oleocanthal, oleacein, and luteolin inhibited CYP3A4. Additionally, luteolin, oleocanthal and ezetimibe had individual inhibitory effects on CYP1A2, CYP2C9 and CYP2D6, respectively. Oleacein had the best binding affinity for LDLR, whereas luteolin had the best binding affinity for PCSK9 and ACLY. Oleacein was biologically effective against pathogens such as Leishmania species, but showed high reactivity with a low energy gap and high malleability. In conclusion, oleacein, oleocanthal and luteolin have potential therapeutic functions in LDL metabolism, which plays a role in atherosclerosis. However, experimental and clinical studies are needed for more evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.